MetaCap

Kura Oncology Inc. (KURA)

NASDAQ: KURAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

6.91-0.44 (-5.99%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

KURA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$634.88M
EPS (TTM)
-$3.30
52-week range
6.75 – 13.90
Day range
6.89 – 7.37
Volume / Avg
1.75M / 2.10M
Beta
—

52-week range

$6.75$13.90

KURA stock today

On Nov 20, KURA ended the session at $6.91, shedding $0.44 (5.99%), versus the S&P 500's 3.70% decline. Shares are 50.3% below their 52-week high of $13.90, set on Aug 25, 2026 and 2.4% above the 52-week low of $6.75, near the bottom of the past year's range. KURA is down 33.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 38.1%.

Kura Oncology has posted a net loss over the last twelve months (EPS of -$3.30), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Kura Oncology

Company profile

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Troy Edward Wilson J.D., Ph.D.
Headquarters
San Diego, CA
Employees
260

Financial highlights

Full financials

In fiscal 2025, Kura Oncology generated $67.5 million in revenue, up 25.2% from fiscal 2024, its 2nd consecutive year of revenue growth. Kura Oncology reported a net loss of $278.7 million, compared with a loss of $174.0 million a year earlier. Operating margin was -449.9%.

Kura Oncology annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$67.48M$53.88M$0——
Growth+25.24%————
Net income$-278.67M$-173.98M$-152.63M$-135.84M$-130.47M
EPS (diluted)$-3.18$-2.02$-2.08$-2.03$-1.97

Analyst forecast

Forecast

Consensus (16 analysts)

strong_buy

Avg. price target

$31.62+357.60%

  • Strong buy 3
  • Buy 12
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $15.00High $76.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.85 vs $-0.83
Surprise
-2.41%

KURA news

All KURA news

Kura Oncology peers

Health Care sector
KURA peer companies
CompanyPrice% ChgMarket capCompare
SGMTSagimet Biosciences Inc. Series A9.08-5.61%$648.02Mvs KURA
JANXJanux Therapeutics Inc.10.08-2.04%$616.73Mvs KURA
ABUSArbutus Biopharma Corporation4.02-1.23%$616.24Mvs KURA
OLMAOlema Oncology Inc.7.02-1.82%$615.00Mvs KURA
NVCTNuvectis Pharma Inc.19.39-2.27%$666.80Mvs KURA
APMDApnimed Inc.16.09-6.70%$669.84Mvs KURA
ANNXAnnexon Inc.3.10-9.09%$591.37Mvs KURA
LXRXLexicon Pharmaceuticals Inc.1.53-8.38%$681.21Mvs KURA

Indexes, lists and sector

Kura Oncology stock FAQ

What is Kura Oncology's stock price today?

KURA last traded at $6.91 as of Nov 20, 4:00 PM EST, down 5.99% on the day. Prices are delayed at least 15 minutes.

Who is Kura Oncology's CEO?

Dr. Troy Edward Wilson J.D., Ph.D. is the chief executive officer of Kura Oncology Inc., which has about 260 employees.

What is the KURA 52-week high?

The 52-week high for KURA is $13.90 and the 52-week low is $6.75. The stock is currently 50.3% below its high.

Compare KURA